{"links":{"html":"https://www.erudio.com/reports/pre1005-nct07285239","json":"https://www.erudio.com/reports/pre1005-nct07285239.json","markdown":"https://www.erudio.com/reports/pre1005-nct07285239.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"pre1005-07285239"}},"request":"https://www.erudio.com/contact?report=pre1005-07285239"},"offer":{"cited_commentary_sources":3,"verified_hcp_statements":28,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":3,"optional":true,"price_per_verified_person_usd":15,"price_usd":45,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"pre1005-nct07285239"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=pre1005-07285239","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/pre1005-nct07285239","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T02:55:00.501792Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":0},"aspects":[{"claim_count":2,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: MRD Negative Status"},{"claim_count":1,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":1,"title":"Primary endpoint: Progression-Free Survival (PFS)"},{"claim_count":5,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":1,"title":"Secondary endpoints"},{"claim_count":6,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":1,"title":"Population and setting"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":1,"title":"The comparison"},{"claim_count":8,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":3,"title":"Safety and tolerability"},{"claim_count":3,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":1,"title":"Design and conduct"},{"claim_count":7,"coverage":"discussed","id":"A1","source_count":2,"title":"DREAMM-9 exchange: access, alternatives and a frontline role"},{"claim_count":8,"coverage":"discussed","id":"A2","source_count":2,"title":"Earlier-study evidence and mechanistic rationale"},{"claim_count":5,"coverage":"discussed","id":"A3","source_count":1,"title":"Enrollment timing, future transplantation and study-team support"},{"claim_count":1,"coverage":"discussed","id":"A4","source_count":1,"title":"Baseline preparation for sequencing-based MRD assessment"}],"counts":{"cited_sources":3,"claims_by_expression_type":{"comparison":1,"interpretation":7,"opinion":10,"restatement":7,"uncertainty":1,"unspecified":2},"claims_by_kind":{"source_observation":28},"clinician_statements":26,"evidence_units":11,"findings":5,"organisational_accounts":1,"people_cited":3,"people_identity_verified":3,"people_total":3,"screened_sources":25,"verified_claims":28},"depth":"thin","findings_index":[{"id":"F1","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":6},"has_counterview":true,"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":2,"passages":4,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Acknowledged activity does not resolve disagreement over a frontline role"},{"id":"F2","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":4},"has_counterview":false,"limitations":4,"links":{"context":0,"support":9},"ma_question":true,"named_voices":1,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"The investigator's efficacy expectation rests on earlier-setting evidence and mechanistic differentiation"},{"id":"F3","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":2,"views":4},"has_counterview":true,"limitations":4,"links":{"context":1,"support":8},"ma_question":true,"named_voices":3,"passages":5,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Scheduling is presented as a tolerability advantage, but reduced ocular harm remains an expectation"},{"id":"F4","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":1},"has_counterview":false,"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":1,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"MRD improvement and high-risk relevance are questions to be tested, not demonstrated benefits"},{"id":"F5","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":1,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"Enrollment flexibility is an explicit research-access message, with eligibility qualifications"}],"medical_affairs_question":"Under what access, ocular-risk and alternative-treatment conditions would a belantamab quadruplet offer an acceptable frontline trade-off?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Activity is acknowledged; the frontline trade-off is disputed"},{"id":"section-2","level":2,"title":"The replacement hypothesis is investigator-led and prospective"},{"id":"section-3","level":2,"title":"Scheduling optimism needs to be separated from observed ocular outcomes"},{"id":"section-4","level":2,"title":"MRD and high-risk enrichment define the anticipated information value"},{"id":"section-5","level":2,"title":"Enrollment encouragement concerns research, not routine adoption"},{"id":"section-6","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F4","shared_claims":2}],"id":"T1","label":"Primary endpoint: MRD Negative Status"},{"findings":[{"id":"F4","shared_claims":1}],"id":"T2","label":"Primary endpoint: Progression-Free Survival (PFS)"},{"findings":[{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":4}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F3","shared_claims":7},{"id":"F5","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T02:55:00.501792Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T03:18:32Z","record_hash":"d27de1f229b000671ec4202a3058519bfde4c8b6f05df71d89d013d4d49c1f1f","release_hash":"210213f5b6b1ecb2c5cb10d521b5aaffa43d1e5f917b761763829f443c8d6f47","report_id":"erudio-nct07285239","run_id":"1bf2a0c4-faa3-4222-94e2-0a090fd6fea9","schema_version":"5.0","slug":"pre1005-07285239","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"PrE1005 asks whether replacing daratumumab with belantamab in initial combination treatment benefits newly diagnosed myeloma patients not undergoing upfront transplantation. A physician described in the source as a principal investigator encourages trial participation, with eligibility remaining a qualification. The physician welcomes the efficacy rationale and dosing approach but presents reduced ocular toxicity as an expectation. In that account, MRD improvement and relevance to high-risk disease remain questions to be tested.","meta_description":"25 sources screened · 28 verified statements (26 from clinicians verified by NPI or staff page) from 3 sources · 5 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-083972fe5745ffbebcba","claim-db6de92a922c300a0983","claim-bed127462dc2fe410b15"],"id":"F5","paraphrase":"A YouTube overview by a physician described in the source as a principal investigator addresses how trial entry and eligibility assessment are handled.","publication_caveats":{"reason":"Publication-specific caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"youtube","source_date":"2026-10-07","title":"Enrollment flexibility is an explicit research-access message, with eligibility qualifications"},{"cited_claim_ids":["claim-5ecf7baa7372030317bc","claim-2bb435a63d1203f247b2","claim-0c5fdb8653b0e0a0eea7"],"id":"F4","paraphrase":"The same physician's YouTube overview addresses which endpoints will assess treatment benefit and how high-risk disease is considered.","publication_caveats":{"reason":"Publication-specific caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"youtube","source_date":"2026-10-07","title":"MRD improvement and high-risk relevance are questions to be tested, not demonstrated benefits"}]},"publication":{"approved_at":"2026-10-29T03:18:32Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":25},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","9 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The views summarized here come from a small set of discussions and cannot establish the prevalence of any opinion among HCPs.","Some additional posts were not fully assessed, and unnamed trial references or different wording may have been missed.","No protocol or publication reporting outcomes for this exact trial was available for this edition; investigator expectations and earlier-study observations cannot be treated as PrE1005 results.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Approved indications and local access to the discussed alternatives were not comprehensively assessed.","The LMIC comparison contains an ambiguous word, and the rare circumstances in which a speaker might accept frontline belantamab are unspecified."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":2,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":3},"count":3,"evidence_window":{"end":"2026-10-07","start":"2026-05-29"},"retrieval_snapshot":"2026-10-29T01:21:30.397126Z","timeline":[{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W32"},{"count":1,"week":"2026-W41"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07285239:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07285239:context","quote_policy":"short_quote_link_out"},{"id":"openfda:b605b541-4bfd-db3e-9710-11c27f6dee6c:20260909","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060501509109108924:5f7a5774-317b-4ea3-97e5-f968422451f2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2077406569503899948:f94d418e-c2ec-4196-99b8-b08381022dc6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2078160204651266480:ecac72c4-f471-4c00-808d-603240ca153b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2079172260867285242:98bf8317-7567-4d29-b8cc-0106e4bf4764","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080634318867603472:2849f33b-aabb-43d7-8a0d-8fec4cf64dc0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2082457877394903478:1376b48d-79ab-4384-8d06-6d3581f8d5f2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2083887934957060114:60968dd3-4a60-4d41-a78c-ef0ef73cac86","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2084664832209428575:2efdc41c-9cc1-4bdc-9a53-ef3bfddc397c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2085422866741502072:7fc953e6-d522-4c06-a164-067e0982aed1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2086920208950682104:f8033a66-fcc4-49fc-80f9-48e7647724e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2087584620816585071:0309b1a4-d581-48b0-b00e-8f68a0afe22f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090051726254424143:cbce0e47-0289-4501-9797-6b5246107a09","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090819324017512527:b9d83152-3fbc-4212-b3e1-dd37d26fab8e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092967706504855641:238fb112-d978-46dd-abd0-6ead71e7760f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093344455071813713:a3417ccf-924f-41a9-b27f-e05faa968435","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094882891641524486:58ff3ba8-ba4e-422a-b2e8-f44cff6047e0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099906178201321473:df31aad8-3a8d-442d-91b0-550e378386b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100598735365374283:2199f3b9-bde9-4007-8d6d-3c4c5a8ced9a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102442892534931967:ce75253a-1082-4353-89ce-ca442ff5c772","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104979590313541657:50548e5c-d60a-44b1-85db-f69ccee959c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107516363199688730:9e5d3a7d-3bc9-4360-8bab-26cfc9ec7ce2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107882824821088572:454b0e9b-5df8-4006-b7fa-2f73a51438cf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112986869172760773:8b3bedf9-08aa-4d73-943b-6020beda0657","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115211517352448144:4856e751-74db-4f4d-89c0-4008093170eb","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:4NsI07KFvHc","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":24,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":25},"count":25,"evidence_window":{"end":"2026-10-27","start":"2026-05-29"},"retrieval_snapshot":"2026-10-29T01:21:30.397126Z","timeline":[{"count":1,"week":"2026-W22"},{"count":2,"week":"2026-W29"},{"count":2,"week":"2026-W30"},{"count":2,"week":"2026-W31"},{"count":2,"week":"2026-W32"},{"count":2,"week":"2026-W33"},{"count":2,"week":"2026-W34"},{"count":2,"week":"2026-W35"},{"count":1,"week":"2026-W36"},{"count":2,"week":"2026-W38"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":3,"week":"2026-W41"},{"count":1,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: arm a: belantamab mafodotin","status":"unmapped"},{"reason":"Unmapped registry intervention: arm b: daratumumab hyaluronidase","status":"unmapped"},{"brand_names":["Velcade"],"label":"bortezomib","slug":"bortezomib"},{"brand_names":["Revlimid"],"label":"lenalidomide","slug":"lenalidomide"},{"brand_names":["Decadron","Dexacen-4","Dexone","Hemady","Hexadrol","Taperdex"],"label":"dexamethasone","slug":"dexamethasone"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Multiple myeloma","slug":"multiple-myeloma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"PrE1005","aliases":["PrE1005","Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","Randomized Phase 3 Trial of Belantamab Mafodotin or Daratumumab in Combination With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma"],"brief_title":"Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","collaborators":["GlaxoSmithKline"],"conditions":["Multiple Myeloma"],"enrollment":{"count":500,"type":"ESTIMATED"},"interventions":[{"name":"Arm A: Belantamab Mafodotin","synonyms":["GSK2857916","Blenrep","Belamaf"],"type":"DRUG"},{"name":"Arm B: Daratumumab Hyaluronidase","synonyms":["DARZALEX FASPRO™"],"type":"DRUG"},{"name":"Bortezomib","synonyms":["Velcade®"],"type":"DRUG"},{"name":"Lenalidomide","synonyms":["Revlimid®"],"type":"DRUG"},{"name":"Dexamethasone","synonyms":["Decadron"],"type":"DRUG"}],"nct_id":"NCT07285239","official_title":"Randomized Phase 3 Trial of Belantamab Mafodotin or Daratumumab in Combination With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2031-11","type":"ESTIMATED"},"primary_endpoints":[{"description":"MRD negative status, defined as achieving MRD negativity at 10-5 sensitivity threshold assessed by NGS at least once during the time of confirmed CR or better response per IMWG criteria by Independent Review Committee (IRC); MRD negativity is determined by the Adaptive Biotechnologies clonoSEQ® assay result","measure":"MRD Negative Status","timeFrame":"Up to 86 months"},{"description":"PFS, defined as the time from the date of randomization to the date of first documented disease progression per IMWG criteria by IRC or death from any cause in the absence of progression, whichever occurs first","measure":"Progression-Free Survival (PFS)","timeFrame":"Up to 86 months"}],"registry_last_updated":"2026-08-17","registry_url":"https://clinicaltrials.gov/study/NCT07285239","short_name":"PrE1005","short_name_basis":"registry_acronym","sponsor":"PrECOG, LLC.","start_date":{"date":"2026-09","type":"ESTIMATED"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"PrE1005","type":"sponsor_study_id"},{"domain":"GlaxoSmithKline","id":"GSK 300057","type":"other"}],"study_type":"INTERVENTIONAL"}}}